Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance

Journal of Leukocyte Biology

Volumn 96, Issue 3, 2014, Pages 397-410

  Jackson, Stephanie R ^a   Yuan, Jinyun ^a   Berrien Elliott, Melissa M ^a   Chen, Collin L ^a   Meyer, Jennifer M ^a   Donlin, Maureen J ^a   Teague, Ryan M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

Author keywords

Effector differentiation immunity; Immunotherapy; Transcription factors

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; GAG ANTIGEN; GAMMA INTERFERON; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EOME; TRANSCRIPTION FACTOR T BET; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTOANTIGEN; CYTOKINE; EOMES PROTEIN, MOUSE; T LYMPHOCYTE RECEPTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; ERYTHROLEUKEMIA; ERYTHROLEUKEMIA CELL; INFLAMMATION; LISTERIOSIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC CHORIOMENINGITIS; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; GENE; GENE EXPRESSION REGULATION; GENETICS; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; KNOCKOUT MOUSE; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LISTERIA; PHYSIOLOGY; SPLEEN; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; AUTOANTIGENS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CLONAL ANERGY; CLONAL DELETION; CYTOKINES; GENE EXPRESSION REGULATION; GENES, RAG-1; IMMUNIZATION; INFLAMMATION; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LISTERIA; LISTERIOSIS; MICE; MICE, KNOCKOUT; SELF TOLERANCE; SPLEEN; T-BOX DOMAIN PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 84907347839     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.1A0913-500RR     Document Type: Article

References (61)

1. Redmond, W. L., Sherman, L. A. (2005) Peripheral tolerance of CD8 T lymphocytes. Immunity 22, 275-284.
2. Teague, R. M., Greenberg, P. D., Fowler, C, Huang, M. Z., Tan, X., Mo-rimoto, J., Dossett, M. L., Huseby, E. S., Ohlen, C. (2008) Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 28, 662-674.
3. Ohlen, C., Kalos, M., Cheng, L. E., Shur, A. C, Hong, D. J., Carson, B. D., Kokot, N. C, Lerner, C. G., Sather, B. D., Huseby, E. S., Greenberg, P. D. (2002) CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195, 1407-1418.
4. Berrien-Elliott, M. M., Jackson, S. R, Meyer, J. M., Rouskey, C. J., Nguyen, T. L., Yagita, H., Greenberg, P., Dipaolo, RJ., Teague, RM. (2013) Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T cell tolerance. Cancer Res. 73, 605-616.
5. Kaech, S. M., Wherry, E. J., Ahmed, R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251-262.
6. Bai, A, Higham, E., Eisen, H. N., Wittrup, K. D., Chen, J. (2008) Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Natl. Acad. Sci. USA 105, 13003-13008.
7. Savage, P. A, Vosseller, K, Kang, C, Larimore, K, Riedel, E., Wojnoon-ski, K, Jungbluth, A. A, Allison, J. P. (2008) Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 319, 215-220.
8. Teague, R M., Sather, B. D., Sacks, J. A., Huang, M. Z., Dossett, M. L., Morimoto, J., Tan, X., Sutton, S. E., Cooke, M. P., Ohlen, C, Greenberg, P. D. (2006) Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12, 335-341.
9. Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R, de Jong, L. A, Vyth-Dreese, F. A, Dellemijn, T. A, Antony, P. A, Spiess, P. J., Palmer, D. C, Heimann, D. M., Klebanoff, C. A, Yu, Z., Hwang, L. N., Feigenbaum, L., Kruisbeek, A. M., Rosenberg, S. A, Restifo, N. P. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.J. Exp. Med. 198, 569-580.
10. Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., Glim-cher, L. H. (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655-669.
11. Pearce, E. L., Mullen, A. C, Martins, G. A, Krawczyk, C. M., Hutchins, A.S., Zediak, V. P., Banica, M., DiCioccio, C. B., Gross, D. A, Mao, C. A, Shen, H., Cereb, N., Yang, S. Y, Lindsten, T., Rossant, J., Hunter, C. A, Reiner, S. L. (2003) Control of effector CD8+ T cell function by the transcription factor eomesodermin. Science 302, 1041-1043.
12. Intlekofer, A. M., Takemoto, N., Wherry, E. J., Longworth, S. A, Northrup, J. T., Palanivel, V. R, Mullen, A. C., Gasink, C. R, Kaech, S. M., Miller, J. D., Gapin, L., Ryan, K, Russ, A. P., Lindsten, T., Orange, J. S., Goldrath, A. W., Ahmed, R, Reiner, S. L. (2005) Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6, 1236-1244.
13. Szabo, S. J., Sullivan, B. M., Stemmann, C, Satoskar, A. R, Sleckman, B.P., Glimcher, L. H. (2002) Distinct effects of T-bet in TH1 lineage commitment and IFN-7 production in CD4 and CD8 T cells. Science 295, 338-342.
14. Zhu, Y, Ju, S., Chen, E., Dai, S., Li, C, Morel, P., Liu, L., Zhang, X., Lu, B.(2010) T-bet and eomesodermin are required for T cell-mediated antitumor immune responses.J. Immunol. 185, 3174-3183.
15. Sullivan, B. M., Juedes, A, Szabo, S. J., von Herrath, M., Glimcher, L. H. (2003) Antigen-driven effector CD8 T cell function regulated by T-bet. Proc. Natl. Acad. Sci. USA 100, 15818-15823.
16. Juedes, A. E., Rodrigo, E., Togher, L., Glimcher, L. H., von Herrath, M. G. (2004) T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetes. J. Exp. Med. 199, 1153-1162.
17. Lord, G. M., Rao, R. M., Choe, H., Sullivan, B. M., Lichtman, A. H., Luscinskas, F. W., Glimcher, L. H. (2005) T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood 106, 3432-3439.
18. Eshima, K, Chiba, S., Suzuki, H., Kokubo, K, Kobayashi, H., Iizuka, M., Iwabuchi, K., Shinohara, N. (2012) Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol. Lett. 144, 7-15.
19. Intlekofer, A. M., Banerjee, A, Takemoto, N., Gordon, S. M., Dejong, C.S., Shin, H., Hunter, C. A, Wherry, E. J., Lindsten, T., Reiner, S. L. (2008) Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321, 408-411.
20. Kao, C, Oestreich, K. J., Paley, M. A, Crawford, A, Angelosanto, J. M., Ali, M. A, Intlekofer, A. M., Boss, J. M., Reiner, S. L., Weinmann, A. S., Wherry, E. J. (2011) Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 12, 663-671.
21. Paley, M. A, Kroy, D. C, Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K, Robertson, E. J., Lauer, G. M., Reiner, S. L., Wherry, E.J. (2012) Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220-1225.
22. Bettelli, E., Sullivan, B., Szabo, S. J., Sobel, R A, Glimcher, L. H., Kuchroo, V. K. (2004) Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200, 79-87.
23. Ishizaki, K, Yamada, A, Yoh, K, Nakano, T., Shimohata, H., Maeda, A, Fujioka, Y, Morito, N., Kawachi, Y, Shibuya, K, Otsuka, F., Shibuya, A, Takahashi, S. (2007) Th1 and type 1 cytotoxic T cells dominate responses in T-bet overexpression transgenic mice that develop contact dermatitis. J. Immunol. 178, 605-612.
24. Neurath, M. F., Weigmann, B., Finotto, S., Glickman, J., Nieuwenhuis, E., Iijima, H., Mizoguchi, A, Mizoguchi, E., Mudter, J., Galle, P. R, Bhan, A, Autschbach, F., Sullivan, B. M., Szabo, S. J., Glimcher, L. H., Blumberg, RS. (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195, 1129-1143.
25. Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Oder-matt, B., Malissen, B., Zinkernagel, R. M., Hengartner, H. (1991) Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65, 305-317.
26. Von Herrath, M. G., Guerder, S., Lewicki, H., Flavell, R. A, Oldstone, M. B. (1995) Coexpression of B7-1 and viral ("self) transgenes in pancreatic /3 cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 3, 727-738.
27. Belz, G. T., Behrens, G. M., Smith, C. M., Miller, J. F., Jones, C, Lejon, K, Fathman, C. G., Mueller, S. N., Shortman, K, Carbone, F. R, Heath, W. R (2002) The CD8a(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196, 1099-1104.
28. Hernandez, J., Aung, S., Redmond, W. L., Sherman, L. A. (2001) Phe-notypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194, 707-717.
29. Redmond, W. L., Wei, C. H., Kreuwel, H. T., Sherman, L. A. (2008) The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen. J. Immunol. 180, 5275-5282.
30. Kurts, C, Carbone, F. R., Barnden, M., Blanas, E., Allison, J., Heath, W. R, Miller, J. F. (1997) CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186, 2057-2062.
31. Schietinger, A., Delrow, J. J., Basom, R S., Blattman, J. N., Greenberg, P. D. (2012) Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335, 723-727.
32. Brockstedt, D. G., Giedlin, M. A, Leong, M. L., Bahjat, K S., Gao, Y, Luckett, W., Liu, W., Cook, D. N., Portnoy, D. A, Dubensky T. W., Jr., (2004) Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101, 13832-13837.
33. Clifton, G. T., Peoples, G. E. (2009) Overcoming cancer immune tolerance and escape. Clin. Cancer Res. 15, 749-751.
34. Ohlen, C, Kalos, M., Hong, D. J., Shur, A. C, Greenberg, P. D. (2001) Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166, 2863-2870.
35. Kondo, Y., Iizuka, M., Wakamatsu, E., Yao, Z., Tahara, M., Tsuboi, H., Sugihara, M., Hayashi, T., Yoh, K, Takahashi, S., Matsumoto, I., Su-mida, T. (2012) Overexpression of T-bet gene regulates murine autoimmune arthritis. Arthritis Rheum. 64, 162-172.
36. Cheever, M. A, Thompson, J. A, Kern, D. E., Greenberg, P. D. (1985) Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. J. Immunol. 134, 3895-3900.
37. Chen, W., Qin, H., Chesebro, B., Cheever, M. A. (1996) Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J. Virol. 70, 7773-7782.
38. Agata, Y, Kawasaki, A, Nishimura, H., Ishida, Y, Tsubata, T., Yagita, H., Honjo, T. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772.
39. Unanue, E. R (1997) Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response. Immunol. Rev. 158, 11-25.
40. Takemoto, N., Intlekofer, A. M., Northrup, J. T., Wherry, E. J., Reiner, S. L. (2006) Cutting edge: IL-12 inversely regulates T-bet and eomeso-dermin expression during pathogen-induced CD8+ T cell differentiation. J. Immunol. 177, 7515-7519.
41. Agarwal, P., Raghavan, A, Nandiwada, S. L., Curtsinger, J. M., Bo-hjanen, P. R, Mueller, D. L., Mescher, M. F. (2009) Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J. Immunol. 183, 1695-1704.
42. Pipkin, M. E., Sacks, J. A, Cruz-Guilloty, F., Lichtenheld, M. G., Bevan, M. J., Rao, A. (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32, 79-90.
43. Morimoto, J., Tan, X., Teague, R M., Ohlen, C, Greenberg, P. D. (2007) Induction of tolerance in CD8+ T cells to a transgenic autoanti-gen expressed in the liver does not require cross-presentation. J. Immunol. 178, 6849-6860.
44. Long, M., Slaiby, A. M., Hagymasi, A. T., Mihalyo, M. A, Lichtler, A. C, Reiner, S. L., Adler, A J. (2006) T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-7 expression. J. Immunol. 176, 1036-1045.
45. Way, S. S., Wilson, C. B. (2004) Cutting edge: immunity and IFN-7 production during Listeria monocytogenes infection in the absence of T-bet. J. Immunol. 173, 5918-5922.
46. Kolumam, G. A, Thomas, S., Thompson, L. J., Sprent, J., Murali-Krishna, K (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202, 637-650.
47. Kreuwel, H. T., Aung, S., Silao, C, Sherman, L. A. (2002) Memory CD8(+) T cells undergo peripheral tolerance. Immunity 17, 73-81.
48. Bercovici, N., Heurtier, A, Vizler, C, Pardigon, N., Cambouris, C, Des-reumaux, P., Liblau, R (2000) Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. J. Immunol. 165, 202-210.
49. Kyburz, D., Aichele, P., Speiser, D. E., Hengartner, H., Zinkernagel, R M., Pircher, H. (1993) T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23, 1956-1962.
50. Lewis, M. D., Miller, S. A, Miazgowicz, M. M., Beima, K M., Weinmann, A. S. (2007) T-bet's ability to regulate individual target genes requires the conserved T-box domain to recruit histone methyltransferase activity and a separate family member-specific transactivation domain. Mol. Cell. Biol. 27, 8510-8521.
51. Curtsinger, J. M., Lins, D. C, Mescher, M. F. (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197, 1141-1151.
52. Steiner, D. F., Thomas, M. F., Hu, J. K, Yang, Z., Babiarz, J. E., Allen, C. D., Matloubian, M., Blelloch, R, Ansel, K M. (2011) MicroRNA-29 regulates T-box transcription factors and interferon-7 production in helper T cells. Immunity 35, 169-181.
53. Smith, K M., Guerau-de-Arellano, M., Costinean, S., Williams, J. L., Bottoni, A, Mavrikis Cox, G., Satoskar, A. R, Croce, C. M., Racke, M. K, Lovett-Racke, A. E., Whitacre, C. C. (2012) MIR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J. Immunol. 189, 1567-1576.
54. Davey, G. M., Kurts, C, Miller, J. F., Bouillet, P., Strasser, A, Brooks, A. G., Carbone, F. R, Heath, W. R (2002) Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J. Exp. Med. 196, 947-955.
55. Bertolino, P., Trescol-Biemont, M. C, Rabourdin-Combe, C. (1998) Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur. J. Immunol. 28, 221-236.
56. Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I., Marson, A. L. (2004) Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200, 1581-1592.
57. Joshi, N. S., Cui, W., Chandele, A, Lee, H. K, Urso, D. R, Hagman, J., Gapin, L., Kaech, S. M. (2007) Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27, 281-295.
58. Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R, Porter, D. L., Rheingold, S. R, Teachey, D. T., Chew, A, Hauck, B., Wright, J. F., Milone, M. C, Levine, B. L., June, C. H. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
59. Morgan, R A, Dudley, M. E., Wunderlich, J. R, Hughes, M. S., Yang, J. C, Sherry, R M., Royal, R E., Topalian, S. L., Kammula, U. S., Res-tifo, N. P., Zheng, Z., Nahvi, A, de Vries, C. R, Rogers-Freezer, L. J., Mavroukakis, S. A, Rosenberg, S. A. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
60. Le, D. T., Brockstedt, D. G., Nir-Paz, R, Hampl, J., Mathur, S., Nemun-aitis, J., Sterman, D. H., Hassan, R, Lutz, E., Moyer, B., Giedlin, M., Louis, J. L., Sugar, E. A, Pons, A, Cox, A. L., Levine, J., Murphy, A. L., Illei, P., Dubensky T. W., Jr., Eiden, J. E., Jaffee, E. M., Laheru, D. A. (2012) A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin. Cancer Res. 18, 858-868.
61. Maciag, P. C, Radulovic, S., Rothman, J. (2009) The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27, 3975-3983.